Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
NAR Cancer|May 6, 2026
Sensitive detection of somatic mutations in GC-rich cancer gene promotersMeifang Qi, Preshita Sanjay Dave, Nicole Francis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian CancersFelipe Batalini, Doga C Gulhan, Victor Mao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial CancerPanagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in LeiomyosarcomaAdrian Marino-Enriquez, Jan Philipp Novotny, Doga C Gulhan, et al.Nature Communications|May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.Nature Communications|March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.Proceedings of the National Academy of Sciences of the United States of America|August 6, 2025
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasisJoanna A Vuille, Cem Tanriover, Ezgi Antmen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionalityMaria Ochoa-de-Olza, Nicolas Rayroux, Martina Imbimbo, et al.Nature|November 19, 2025
Hepatic zonation determines tumorigenic potential of mutant β-cateninAlexander Raven, Kathryn Gilroy, Hu Jin, et al.Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.Pageof 4